A clinical stage gene therapy company focused on preserving vision through a one-time treatment for age-related macular degeneration (AMD) using HMR59, currently undergoing FDA clinical trial testing. HMR59 aims to treat both dry and wet forms of AMD with a simple injection during office visits.